Synereca develops novel compounds intended to restore and enhance the activity of existing antibiotics against drug-resistant Gram-negative bacteria. Preclinical results have shown that combining the company’s compounds with current antibiotics can restore and enhance activity against resistant pathogens that cause difficult-to-treat infections. The company intends to use newly raised funds to develop these compounds to address bacterial resistance to current antibiotics. Synereca is led by CEO Clayton Duncan and is a portfolio company of Accele Biopharma. It maintains laboratories in Oklahoma City and North Carolina. To date the company has received $2.5m in funding. Synereca Pharmaceutics is a research-stage biopharmaceutical company developing novel orally active drugs to restore or increase the effectiveness of existing antibiotics. Its programs focus on potentiating antibiotics against drug-resistant Gram-negative bacteria. The company has two lead research programs: compounds that potentiate Colistin without enhancing toxicity, and inhibitors of RecA, a key bacterial DNA repair enzyme involved in resistance development and transmission. Synereca intends to use the recent financing to advance these research programs. The company raised $1.4M in convertible debt financing to support these efforts. Synereca is based in Oklahoma City, OK, and is led by Clayton Duncan as acting CEO.

Total raised

$2M

Funding rounds

2

Latest round

Equity

Latest activity

Aug 2015